Assess and Compare the Infertility Rates Associated with Cyclophosphamide and Lostine in Cancer Patients

Murooj Luai Majeed  Altimimi

doi:10.51699/cajmns.v7i1.3071

Authors

Murooj Luai Majeed Altimimi Assistant Professor in Pharmacology in the Pharmacology Department at Kufa Medical College, Al-Najaf, Iraq.

DOI:

https://doi.org/10.51699/cajmns.v7i1.3071

Keywords:

COMPARE, CYCLOPHOSPHAMIDE, LOSTINE, CANCER, PATIENTS, HORMONAL LEVELS, QUALITY-OF-LIFE, INFERTILITY, FSH, LH, ESTRADIOL

Abstract

Background: Infertility is a major issue in cancer survivors, particularly after they are subjected to chemotherapy. Alkylating chemotherapeutic agents commonly used, such as cyclophosphamide, has been reported to have gonadotoxic effects. However, in comparison, the reproductive consequences of the newer chemotherapeutic agent of Lostine are still poorly defined.

Purpose: The purpose of the study was to compare and contrast the levels of infertility, changes in hormonal levels, and quality-of-life parameters between cancer patients who received Cyclophosphamide and those who received Lostine.

Methods: A comparative cohort study was conducted among 140 patients with cancers, where in 70 patients were in a group that was treated with Cyclophosphamide, and 70 patients were treated with Lostine. The information, including demographic characteristics, infertility, and latency to infertility, hormonal levels (FSH, LH, estradiol), quality-of-life measures, adverse outcomes, and patient satisfaction, were carefully recorded. Determinants of infertility were identified by use of logistic regression analyses.

Findings: Infertility was much higher in the Cyclophosphamide group (42.9 percent) as compared with the Lostine group (21.4 percent). The gonadal dysfunction was shown by the strong levels of FSH and LH in the presence of decreased estradiol in cyclophosphamide-treated patients. On the contrary, the Lostine group had relatively steady hormonal values, better patient satisfaction (80% vs. 65%), and quality-of-life ratings (70 vs. 60). The cases of adverse events were significantly higher in recipients of Cyclophosphamide. Cyclophosphamide exposure and hormone perturbations were found to be some of the strong predictors of infertility with the help of logistic regression analysis.

Conclusions: Cyclophosphamide has a significantly increased risk of infertility and hormonal imbalance compared to Lostine. Strategies to preserve fertility and extensive counselling need to be part of it, especially among younger patients. Future studies are justified to outline the long-term reproductive outcomes of Lostine.

References

C. Marzorati, S. Riva, and G. Pravettoni, “Who is a cancer survivor? A systematic review of published definitions,” J. Cancer Educ., vol. 32, no. 2, pp. 228–237, 2017.

Ethics Committee of the American Society of Reproductive Medicine, “Fertility preservation and reproduction in patients facing gonadotoxic therapies: An Ethics Committee opinion,” Fertil. Steril., vol. 110, no. 6, pp. 380–386, 2018.

J. M. Letourneau, E. E. Ebbel, and P. P. Katz, “Pretreatment fertility counseling and fertility preservation improve the quality of life in reproductive-age women with cancer,” Cancer, vol. 118, no. 6, pp. 1710–1717, 2012.

J. S. Jeruss and T. K. Woodruff, “Preservation of fertility in patients with cancer,” N. Engl. J. Med., vol. 360, no. 9, pp. 902–911, 2009.

K. E. Dillon and C. R. Gracia, “Pediatric and young adult patients and oncofertility,” Curr. Treat. Options Oncol., vol. 13, no. 2, pp. 161–173, 2012.

M. Lambertini et al., “Cancer and fertility preservation: International recommendations from an expert meeting,” BMC Med., vol. 14, no. 1, pp. 1–16, 2016.

A. Ferrari et al., “Adolescents and young adults (AYA) with cancer: A position paper from the AYA Working Group of ESMO and SIOPE,” ESMO Open, vol. 6, Art. no. 100096, 2021.

B. Anderson and K. Albritton, Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer, Bethesda, MD, USA: National Cancer Institute, 2006.

K. D. Miller et al., “Cancer statistics for adolescents and young adults, 2020,” CA Cancer J. Clin., vol. 70, pp. 443–459, 2020.

L. You et al., “Worldwide cancer statistics of adolescents and young adults in 2019: A systematic analysis of the Global Burden of Disease Study 2019,” ESMO Open, vol. 6, Art. no. 100255, 2021.

S. C. Södergren et al., “Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer,” Qual. Life Res., vol. 26, pp. 1659–1672, 2017.

R. S. Barberino et al., “Protective effects of antioxidants on cyclophosphamide-induced ovarian toxicity,” Biopreserv. Biobank., vol. 21, no. 2, pp. 121–141, 2023.

E. J. Chow et al., “Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999,” Lancet Oncol., vol. 17, pp. 567–576, 2016.

R. A. Anderson et al., “The impact of cancer on subsequent chance of pregnancy: A population-based analysis,” Hum. Reprod., vol. 33, pp. 1281–1290, 2018.

A. Di Meglio, I. Vaz-Luis, and B. Pistilli, “Impact of systemic anticancer therapy on fertility,” in Fertility Challenges and Solutions in Women with Cancer, Berlin, Germany: Springer, 2020, pp. 67–80.

K. D. Dinas, “Impact of breast cancer treatment on fertility,” in Diseases of the Breast during Pregnancy and Lactation, Berlin, Germany: Springer, 2020, p. 1252.

K. C. T. Vo and K. Kawamura, “Female oncofertility: Current understandings, therapeutic approaches, controversies, and future perspectives,” J. Clin. Med., vol. 10, Art. no. 5690, 2021.

V. Martelli et al., “Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women,” Breast Cancer Targets Ther., vol. 13, pp. 341–352, 2021.

M. Cengiz, “Protective effects of carvacrol, the main component of thyme, on cyclophosphamide-induced reproductive system damage in rats,” Turk. J. Agric. Res., no. 4, p. 171.

T. Safarnavadeh, “Antioxidants and infertility treatment: The role of Satureja khuzestanica: A mini-systematic review,” Iran. J. Reprod. Med., no. 9, p. 61.

H. A. Al-Salih, “The pathological features of cyclophosphamide-induced multi-organ toxicity in male Wistar rats,” Syst. Rev. Pharm., no. 11, p. 45.

N. A. Al-Niwehee, “Effect of cyclophosphamide treatment during the embryonic period on fertility of adult male mice,” Iraqi J. Sci., vol. 60, p. 706.

P. A. Parekh, “Regulation of GDNF expression in Sertoli cells,” Reproduction, vol. 157, p. R95.